These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 2105930

  • 1. Binding of tissue-type plasminogen activator with human endothelial cell monolayers. Characterization of the high affinity interaction with plasminogen activator inhibitor-1.
    Russell ME, Quertermous T, Declerck PJ, Collen D, Haber E, Homcy CJ.
    J Biol Chem; 1990 Feb 15; 265(5):2569-75. PubMed ID: 2105930
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The majority of type 1 plasminogen activator inhibitor associated with cultured human endothelial cells is located under the cells and is accessible to solution-phase tissue-type plasminogen activator.
    Schleef RR, Podor TJ, Dunne E, Mimuro J, Loskutoff DJ.
    J Cell Biol; 1990 Jan 15; 110(1):155-63. PubMed ID: 2104856
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. On the reversible interaction of plasminogen activator inhibitor-1 with tissue-type plasminogen activator and with urokinase-type plasminogen activator.
    Lijnen HR, Van Hoef B, Collen D.
    J Biol Chem; 1991 Mar 05; 266(7):4041-4. PubMed ID: 1900284
    [Abstract] [Full Text] [Related]

  • 8. The interaction of recombinant tissue type plasminogen activator and recombinant plasminogen activator (r-PA/BM 06.022) with human endothelial cells.
    Mulder M, Kohnert U, Fischer S, van Hinsbergh VW, Verheijen JH.
    Blood Coagul Fibrinolysis; 1997 Mar 05; 8(2):124-33. PubMed ID: 9518044
    [Abstract] [Full Text] [Related]

  • 9. Catabolism of tissue-type plasminogen activator by the human hepatoma cell line Hep G2. Modulation by plasminogen activator inhibitor type 1.
    Morton PA, Owensby DA, Sobel BE, Schwartz AL.
    J Biol Chem; 1989 May 05; 264(13):7228-35. PubMed ID: 2540181
    [Abstract] [Full Text] [Related]

  • 10. Determinants of induction of increased synthesis of plasminogen activator inhibitor type-1 in human endothelial cells by t-PA.
    Fujii S, Sobel BE.
    Thromb Haemost; 1992 Feb 03; 67(2):233-8. PubMed ID: 1621243
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Interaction of tissue-type plasminogen activator and plasminogen activator inhibitor 1 on the surface of endothelial cells.
    Sakata Y, Okada M, Noro A, Matsuda M.
    J Biol Chem; 1988 Feb 05; 263(4):1960-9. PubMed ID: 3123483
    [Abstract] [Full Text] [Related]

  • 19. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.
    Horn IR, van den Berg BM, Moestrup SK, Pannekoek H, van Zonneveld AJ.
    Thromb Haemost; 1998 Nov 05; 80(5):822-8. PubMed ID: 9843178
    [Abstract] [Full Text] [Related]

  • 20. Reactivated recombinant plasminogen activator inhibitor-1 (rPAI-1) effectively prevents thrombolysis in vivo.
    Vaughan DE, Declerck PJ, Van Houtte E, De Mol M, Collen D.
    Thromb Haemost; 1992 Jul 06; 68(1):60-3. PubMed ID: 1514173
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.